Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

Authors: Michael Heise, Anja Lautem, Johanna Knapstein, Jörn M Schattenberg, Maria Hoppe-Lotichius, Daniel Foltys, Nina Weiler, Anca Zimmermann, Arno Schad, Dirk Gründemann, Gerd Otto, Peter R Galle, Marcus Schuchmann, Tim Zimmermann

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).

Methods

OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs.

Results

Real time PCR showed a downregulation of SLC22A1 and SLC22A3 in HCC compared to TST (p ≤ 0.001). A low SLC22A1 expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, SLC22A1 was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low SLC22A1 expression (< median) showed a higher SLC22A3 expression compared to HCC with high SLC22A1 expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the SLC22A3 expression.
In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.

Conclusion

The downregulation of OCT1 is associated with tumor progression and a worse patient survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRefPubMed El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRefPubMed
2.
go back to reference Schwartz M: Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004, 127: S268-S276. 10.1053/j.gastro.2004.09.041.CrossRefPubMed Schwartz M: Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004, 127: S268-S276. 10.1053/j.gastro.2004.09.041.CrossRefPubMed
3.
go back to reference Breidert T, Spitzenberger F, Grundemann D, Schomig E: Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol. 1998, 125: 218-224. 10.1038/sj.bjp.0702065.CrossRefPubMedPubMedCentral Breidert T, Spitzenberger F, Grundemann D, Schomig E: Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol. 1998, 125: 218-224. 10.1038/sj.bjp.0702065.CrossRefPubMedPubMedCentral
4.
go back to reference Bachmakov I, Glaeser H, Endress B, Morl F, Fromm MF: Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab. 2009, 11: 1080-1083. 10.1111/j.1463-1326.2009.01076.x.CrossRefPubMed Bachmakov I, Glaeser H, Endress B, Morl F, Fromm MF: Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab. 2009, 11: 1080-1083. 10.1111/j.1463-1326.2009.01076.x.CrossRefPubMed
5.
go back to reference Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000, 131: 71-79. 10.1038/sj.bjp.0703518.CrossRefPubMedPubMedCentral Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000, 131: 71-79. 10.1038/sj.bjp.0703518.CrossRefPubMedPubMedCentral
6.
go back to reference Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998, 273: 30915-30920. 10.1074/jbc.273.47.30915.CrossRefPubMed Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998, 273: 30915-30920. 10.1074/jbc.273.47.30915.CrossRefPubMed
7.
go back to reference Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998, 1: 349-351. 10.1038/1557.CrossRefPubMed Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998, 1: 349-351. 10.1038/1557.CrossRefPubMed
8.
go back to reference Jonker JW, Schinkel AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004, 308: 2-9.CrossRefPubMed Jonker JW, Schinkel AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004, 308: 2-9.CrossRefPubMed
9.
go back to reference Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I: Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007, 52: 117-122. 10.1007/s10038-006-0087-0.CrossRefPubMed Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I: Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007, 52: 117-122. 10.1007/s10038-006-0087-0.CrossRefPubMed
10.
go back to reference Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004, 104: 3739-3745. 10.1182/blood-2003-12-4276.CrossRefPubMed Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004, 104: 3739-3745. 10.1182/blood-2003-12-4276.CrossRefPubMed
11.
go back to reference Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006, 66: 8847-8857. 10.1158/0008-5472.CAN-06-0769.CrossRefPubMedPubMedCentral Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006, 66: 8847-8857. 10.1158/0008-5472.CAN-06-0769.CrossRefPubMedPubMedCentral
12.
go back to reference Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE: hOCT 1 and resistance to imatinib. Blood. 2005, 106: 1133-1134. 10.1182/blood-2005-02-0694. author replyCrossRefPubMed Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE: hOCT 1 and resistance to imatinib. Blood. 2005, 106: 1133-1134. 10.1182/blood-2005-02-0694. author replyCrossRefPubMed
13.
go back to reference White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006, 108: 697-704. 10.1182/blood-2005-11-4687.CrossRefPubMed White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006, 108: 697-704. 10.1182/blood-2005-11-4687.CrossRefPubMed
14.
go back to reference White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007, 110: 4064-4072. 10.1182/blood-2007-06-093617.CrossRefPubMed White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007, 110: 4064-4072. 10.1182/blood-2007-06-093617.CrossRefPubMed
15.
go back to reference Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007, 35: 1333-1340. 10.1124/dmd.107.014902.CrossRefPubMed Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007, 35: 1333-1340. 10.1124/dmd.107.014902.CrossRefPubMed
16.
go back to reference Cui R, Okada Y, Jang SG, Ku JL, Kamatani Y, Hosono N, Tsunoda T, Kumar V, Tanikawa C, Kamatani N, Yamada R, Kubo M, Nakamura Y, Matsuda K: Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut. 2011, 60: 799-805. 10.1136/gut.2010.215947.CrossRefPubMedPubMedCentral Cui R, Okada Y, Jang SG, Ku JL, Kamatani Y, Hosono N, Tsunoda T, Kumar V, Tanikawa C, Kamatani N, Yamada R, Kubo M, Nakamura Y, Matsuda K: Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut. 2011, 60: 799-805. 10.1136/gut.2010.215947.CrossRefPubMedPubMedCentral
17.
go back to reference Park T, Yi SG, Shin YK, Lee S: Combining multiple microarrays in the presence of controlling variables. Bioinformatics. 2006, 22: 1682-1689. 10.1093/bioinformatics/btl183.CrossRefPubMed Park T, Yi SG, Shin YK, Lee S: Combining multiple microarrays in the presence of controlling variables. Bioinformatics. 2006, 22: 1682-1689. 10.1093/bioinformatics/btl183.CrossRefPubMed
18.
go back to reference Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M: Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006, 12: 1260-1267. 10.1002/lt.20837.CrossRefPubMed Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M: Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006, 12: 1260-1267. 10.1002/lt.20837.CrossRefPubMed
19.
go back to reference Verhaagh S, Schweifer N, Barlow DP, Zwart R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics. 1999, 55: 209-218. 10.1006/geno.1998.5639.CrossRefPubMed Verhaagh S, Schweifer N, Barlow DP, Zwart R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics. 1999, 55: 209-218. 10.1006/geno.1998.5639.CrossRefPubMed
20.
go back to reference Zwart R, Sleutels F, Wutz A, Schinkel AH, Barlow DP: Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev. 2001, 15: 2361-2366. 10.1101/gad.206201.CrossRefPubMedPubMedCentral Zwart R, Sleutels F, Wutz A, Schinkel AH, Barlow DP: Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev. 2001, 15: 2361-2366. 10.1101/gad.206201.CrossRefPubMedPubMedCentral
21.
go back to reference Staal YC, van Herwijnen MH, van Schooten FJ, van Delft JH: Modulation of gene expression and DNA adduct formation in HepG2 cells by polycyclic aromatic hydrocarbons with different carcinogenic potencies. Carcinogenesis. 2006, 27: 646-655.CrossRefPubMed Staal YC, van Herwijnen MH, van Schooten FJ, van Delft JH: Modulation of gene expression and DNA adduct formation in HepG2 cells by polycyclic aromatic hydrocarbons with different carcinogenic potencies. Carcinogenesis. 2006, 27: 646-655.CrossRefPubMed
22.
go back to reference Clark RE, Davies A, Pirmohamed M, Giannoudis A: Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008, 49: 639-642. 10.1080/10428190701858823.CrossRefPubMed Clark RE, Davies A, Pirmohamed M, Giannoudis A: Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008, 49: 639-642. 10.1080/10428190701858823.CrossRefPubMed
23.
go back to reference Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A: Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008, 14: 3141-3148. 10.1158/1078-0432.CCR-07-4913.CrossRefPubMed Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A: Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008, 14: 3141-3148. 10.1158/1078-0432.CCR-07-4913.CrossRefPubMed
24.
go back to reference Lovejoy KS, Todd RC, Zhang S, McCormick MS, D'Aquino JA, Reardon JT, Sancar A, Giacomini KM, Lippard SJ: cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci USA. 2008, 105: 8902-8907. 10.1073/pnas.0803441105.CrossRefPubMedPubMedCentral Lovejoy KS, Todd RC, Zhang S, McCormick MS, D'Aquino JA, Reardon JT, Sancar A, Giacomini KM, Lippard SJ: cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci USA. 2008, 105: 8902-8907. 10.1073/pnas.0803441105.CrossRefPubMedPubMedCentral
25.
go back to reference Theile D, Grebhardt S, Haefeli WE, Weiss J: Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009, 78: 1366-1373. 10.1016/j.bcp.2009.07.006.CrossRefPubMed Theile D, Grebhardt S, Haefeli WE, Weiss J: Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009, 78: 1366-1373. 10.1016/j.bcp.2009.07.006.CrossRefPubMed
26.
go back to reference Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T: Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2008, 62: 577-584. 10.1007/s00280-007-0640-3.CrossRefPubMed Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T: Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2008, 62: 577-584. 10.1007/s00280-007-0640-3.CrossRefPubMed
27.
go back to reference Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008, 36: 2299-2306. 10.1124/dmd.108.023168.CrossRefPubMed Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008, 36: 2299-2306. 10.1124/dmd.108.023168.CrossRefPubMed
28.
go back to reference Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009, 69: 1494-1501. 10.1158/0008-5472.CAN-08-2483.CrossRefPubMed Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009, 69: 1494-1501. 10.1158/0008-5472.CAN-08-2483.CrossRefPubMed
29.
go back to reference Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE: Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008, 83: 258-264. 10.1038/sj.clpt.6100268.CrossRefPubMed Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE: Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008, 83: 258-264. 10.1038/sj.clpt.6100268.CrossRefPubMed
30.
go back to reference Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005, 16: 129-136. 10.1097/00001813-200502000-00003.CrossRefPubMed Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005, 16: 129-136. 10.1097/00001813-200502000-00003.CrossRefPubMed
31.
go back to reference Morrow CJ, Ghattas M, Smith C, Bönisch H, Bryce RA, Hickinson DM, Green TP, Dive C: Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res. 2010, 70: 5931-5941. 10.1158/0008-5472.CAN-10-0694.CrossRefPubMedPubMedCentral Morrow CJ, Ghattas M, Smith C, Bönisch H, Bryce RA, Hickinson DM, Green TP, Dive C: Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res. 2010, 70: 5931-5941. 10.1158/0008-5472.CAN-10-0694.CrossRefPubMedPubMedCentral
Metadata
Title
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance
Authors
Michael Heise
Anja Lautem
Johanna Knapstein
Jörn M Schattenberg
Maria Hoppe-Lotichius
Daniel Foltys
Nina Weiler
Anca Zimmermann
Arno Schad
Dirk Gründemann
Gerd Otto
Peter R Galle
Marcus Schuchmann
Tim Zimmermann
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-109

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine